We are live on ! Find out more
FATE icon

Fate Therapeutics
FATE

60 hedge funds and large institutions have $86.2M invested in Fate Therapeutics in 2017 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 14

23% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 13

13% more funds holding

Funds holding: 53 → 60 (+7)

3.81% more ownership

Funds ownership: 60.47% → 64.28% (+3.8%)

24% less capital invested

Capital invested by funds: $114M → $86.2M (-$27.7M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
60
Holders Change
+7
Holders Change %
+13.21%
% of All Funds
1.5%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
21
Increased
16
Reduced
13
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$6.02M
2
CC
Casdin Capital
New York
+$2.11M
3
State Street
State Street
Massachusetts
+$1.7M
4
Northern Trust
Northern Trust
Illinois
+$1.28M
5
6CM
683 Capital Management
New York
+$453K

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$5.95M
2
KCM
Kingdon Capital Management
New York
-$2.15M
3
Millennium Management
Millennium Management
New York
-$545K
4
SCM
Segantii Capital Management
Hong Kong
-$182K
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$173K
Name Holding Trade Value Shares
Change 		Change in
Stake
California State Teachers Retirement System (CalSTRS)
26
California State Teachers Retirement System (CalSTRS)
California
$219K +$259K +67,500 New
Charles Schwab
27
Charles Schwab
California
$214K +$253K +66,000 New
Connor, Clark & Lunn Investment Management (CC&L)
28
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$206K +$85.1K +22,200 +54%
Millennium Management
29
Millennium Management
New York
$174K -$545K -142,314 -73%
Jacobs Levy Equity Management
30
Jacobs Levy Equity Management
New Jersey
$162K -$41K -10,700 -18%
Neuberger Berman Group
31
Neuberger Berman Group
New York
$161K -$72.4K -18,900 -28%
UBS Group
32
UBS Group
Switzerland
$141K +$167K +43,625 New
Deutsche Bank
33
Deutsche Bank
Germany
$141K +$168K +43,925 New
RhumbLine Advisers
34
RhumbLine Advisers
Massachusetts
$133K +$157K +40,967 New
New York State Common Retirement Fund
35
New York State Common Retirement Fund
New York
$131K +$155K +40,500 New
TC
36
TFS Capital
Pennsylvania
$111K -$78.5K -20,491 -38%
State of Wisconsin Investment Board
37
State of Wisconsin Investment Board
Wisconsin
$97K +$115K +30,000 New
PAM
38
Panagora Asset Management
Massachusetts
$96K – – –
Squarepoint
39
Squarepoint
New York
$94K – – –
Creative Planning
40
Creative Planning
Kansas
$91K +$19.2K +5,000 +22%
AIG
41
American International Group
New York
$77K +$90.6K +23,650 New
Dimensional Fund Advisors
42
Dimensional Fund Advisors
Texas
$76K +$90K +23,500 New
JP Morgan Chase
43
JP Morgan Chase
New York
$68K +$72.2K +18,844 +870%
NFA
44
Nationwide Fund Advisors
Ohio
$68K +$80.9K +21,117 New
Invesco
45
Invesco
Georgia
$67K +$31.7K +8,271 +66%
Barclays
46
Barclays
United Kingdom
$38K -$51.6K -13,475 -54%
SO
47
STRS Ohio
Ohio
$35K +$42.5K +11,100 New
GC
48
Guggenheim Capital
Illinois
$33K +$39.5K +10,300 New
CB
49
Community Bank
New York
$21K – – –
Legal & General Group
50
Legal & General Group
United Kingdom
$18K +$21.6K +5,627 New
1
2
3

FATE Hedge Fund Activity: Q2 2017 in Review

60 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q2 2017, worth a combined $86.2M — down 24% from $114M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new FATE positions and 14 closed out — a net gain of 7 holders — while 16 added to existing stakes and 13 trimmed.

The largest buyer was BlackRock, adding an estimated $6.02M. The largest seller was BVF Inc, cutting an estimated $5.95M.

  • 60 institutional investors held Fate Therapeutics (FATE) as of Q2 2017, up from 53 in Q1 2017.
  • Funds reported $86.2M of Fate Therapeutics stock for Q2 2017, down 24% quarter-over-quarter.
  • 21 funds opened new Fate Therapeutics positions in Q2 2017 and 14 closed out, a net change of +7 holders.
  • The largest Fate Therapeutics buyer in Q2 2017 was BlackRock, an estimated $6.02M added.
  • The largest Fate Therapeutics seller in Q2 2017 was BVF Inc, an estimated $5.95M sold.

Based on aggregated 13F filings for Q2 2017.